Skip to main content

Table 1 Patient characteristics in each treatment arm

From: Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

Characteristic FEC → Doc FEC → Doc/Gem
Mean or n SD or % Mean or n SD or %
Age 53.9 10.4 53.1 10.6
BMI 26.3 5.1 26.2 5.
Tumor stage
 pT1 771 40.6 781 42.1
 pT2 992 52.3 960 51.7
 pT3 109 5.7 89 4.8
 pT4 26 1.4 26 1.4
Grade
 G1 79 4.2 97 5.2
 G2 914 48.2 891 48.0
 G3 905 47.7 868 46.8
Nodal status
 pN+ 1264 66.6 1217 65.6
 pN0 634 33.4 639 34.4
Tumor type
 Ductal 1558 82.1 1524 82.1
 Lobular 213 11.2 206 11.1
 Other 127 6.7 126 6.8
ER
 Negative 610 32.1 642 34.6
 Positive 1288 67.9 1214 65.4
PR
 Negative 768 40.5 757 40.8
 Positive 1130 59.5 1099 59.2
HER2
 Negative 1457 76.8 1413 76.1
 Positive 441 23.2 443 23.9
Menopausal status
 Premenopausal 775 40.8 790 42.6
 Postmenopausal 1123 59.2 1066 57.4
Adjuvant antihormonal therapy 1360 72.3 1317 71.4
Adjuvant trastuzumab therapy 378 20.1 376 20.4
Adjuvant radiotherapy 1601 85.1 1553 84.2
  1. BMI body mass index, Doc docetaxel, ER estrogen receptor, FEC 5-fluoroucacil, epirubicin, and cyclophosphamide, Gem gemcitabine, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, SD standard deviation